TVTX - Earnings announcements

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere's pipeline Company to host conference call June 2, 2026 at 8:30 a.m. ET Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kina

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million FDA approval in FSGS expands total addressable FILSPARI patient population in the U.S. to more than 100,000; first FSGS patients treated within one week of approval First new patient dosed in restarted Phase 3 HARMONY Study of pegtibatinase; Topline data expected 2H 2027 Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2026 financial results and provided a corporate update. "This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinf

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company

FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI expands total addressable population to more than 100,000 patients in the U.S, including more than 30,000 patients with FSGS Label aligns with KDIGO clinical practice guidelines for managing patients with FSGS Company to host conference call April 13, 2026, at 6:45 p.m. ET Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulo

U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi

U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million Retired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation 2025 KDIGO guidelines and streamlined REMS monitoring strengthen FILSPARI's position as a foundational, nephroprotective therapy for IgAN Company well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26 Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical

U.S. net product sales of FILSPARI® (sparsentan) grew 165% year-over-year to $71.9 million in 2Q 2025; 745 new PSFs received in the quarter sNDA seeking full approval of FILSPARI for FSGS accepted for review; PDUFA target action date set for January 13, 2026 Total revenue for 2Q 2025 was $114.4 million, including net product sales of $94.8 million Cash, cash equivalents, and marketable securities totaled approximately $319.5 million as of June 30, 2025 Travere Therapeutics, Inc., (NASDAQ:TVTX) today reported its second quarter 2025 financial results and provided a corporate update. "We continue to make strong progress against our strategic priorities, putting Travere on a trajecto

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical

Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration (FDA) and plans to submit a supplemental New Drug Application (sN

Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FSGS sNDA requesting modification of liver monitoring for FILSPARI submitted to FDA Net product sales of FILSPARI totaled $35.6 million for the third quarter of 2024; 505 new PSFs received in the period Total revenue for the third quarter of 2024 was $62.9 million, including net product sales of $61.0 million SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today reported its third quarter 2024 financial result

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for li

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the HARMONY Study. Patients currently enrolled in pegtibatinase studies continue to receive study medication from small scale batches which are unaffected by the scale-up process. Currently enrolled patients will be able to continue on study medication as

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN

Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product sales of FILSPARI totaled $27.1 million for the second quarter of 2024 representing 37% growth over the previous quarter Company well-positioned for September 5, 2024 PDUFA target action date for conversion of the U.S. accelerated approval of FILSPARI to full approval in IgAN Total revenue for the second quarter of 2024 was $54.1 million, including net product sales of $52.2 million Cash, cash equivalents, and marketable securities, as of June 30, 2024, totaled $325.4 million SAN DIEGO, Au

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for li

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe

FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new patient start forms (PSFs) for FILSPARI in Q1 2024; Total of 1,963 PSFs received since launch Net product sales of FILSPARI totaled $19.8 million for the first quarter of 2024 European Commission recently granted conditional marketing authorization (CMA) to FILSPARI for the treatment of IgAN in Europe; first launch in European markets anticipated in H2 2024 First patients dosed in pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria (HCU); topline data a

SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rar

Conference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. "2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean-infrastructure, high-margin business," said Todd Davis, CEO of Ligand. "We enhanced our deal making capabilities with the strengthening of our senior team and opening of

Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval CHMP opinion on potential approval in Europe for sparsentan in IgAN anticipated in Q1 2024 Pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria (HCU) enrolling; topline data anticipated in 2026 Net product sales of $39.9 million for Q4 2023; $127.5 million for FY 2023 Cash, cash equivalents, and marketable securities as of December 31, 2023,

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

          Received 430 new patient start forms for FILSPARI® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow             Net product sales of FILSPARI totaled $8 million for the third quarter of 2023             Phase 3 PROTECT and DUPLEX Studies of sparsentan presented as ASN Kidney Week Late Breakers and simultaneously published in The Lancet and NEJM, respectively             Completed sale of bile acid product portfolio for up to $445 million including potential future milestone-based payments, advancing strategy to deliver new treatment standards from pipeline and strengthening financial foundation             Cash, cash equivalents, an

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for lif

FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year) [p=0.037]. Patients treated with FILSPARI over two years exhibited one of the slowest annual rates of kidney function decline seen in a clinical trial of IgAN patients (-2.7 to -2.9 mL/min/1.73m2 per year)eGFR chronic slope was statistically significant with respect to the confirmatory endpoint for the EUAll topline efficacy endpoints favored FILSPARIFILSPARI was well-tolerated with a consistent safety profile comparable to irbesartan across all clinical trials conducted to date, supporting long-term

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w

•   Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN) •   Net product sales of FILSPARI totaled $3.5 million for the second quarter of 2023; $6.5 million for first four and a half months since approval •   Company reported positive topline results from Cohort 6 in the Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU); Phase 3 study expected to initiate by year-end •   Recently announced agreement to sell bile acid product portfolio for up to $445 million, advances strategy to deliver new treatment standards from pipeli

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for lif

Mirum to acquire all of Travere's rights and assets related to Cholbam® and Chenodal® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $210 million, funding upfront payment Expands Mirum's leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity Advances Travere's strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation Mirum to host conference call today, July 17, 2023, at 8:30 a.m. ET/5:30 a.m. PT Mirum Pharmace

Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline Pegtibatinase has been generally well-tolerated to date The Company is engaging with regulators and expects to initiate a pivotal Phase 3 Study by year-end 2023 Company to host conference call and webcast today at 8.30 a.m. ET SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment Sparsentan was well-tolerated with a consistent safety profile across all clinical trials conducted to date and comparable to irbesartan Company to host conference call and webcast today at 4:30pm ET SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual En

SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for

Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN) European Medicines Agency (EMA) review decision for potential conditional approval of sparsentan in IgAN anticipated in second half of 2023 Pivotal DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) on track to report topline data from confirmatory two-year endpoints in second quarter of 2023 Net product sales of $52 million for the fourth quarter of 2022; $201 million for the full year 2022 SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today rep

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. active control, irbesartan Company to host conference call February 17, 2023 4:30pm ET SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a uri

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close of the U.S. financial markets. Management will provide an update on the financial results and provide a business update in a webcast on February 23, 2023, at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we a

EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for sparsentan in IgAN set for February 17, 2023 Net product sales of $50.8 million for the third quarter of 2022 SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its third quarter 2022 financial results and provided a corporate update. European Medicines Agency (EMA) accepted for review the conditional marketing authorization (CMA) application for sparsentan for the treatment of IgAN in Europe; review decision on potential approval expected in seco

SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date:Thursday, October 27, 2022Time:4:30 p.m. ETDial-in numbers:+1 (888) 394-8218 (U.S.) or +1 (323) 794-2551 (International)Confirmation code:3327353Live webcast:Travere.com in the "Events & Presentations" section of the "Investors" page A replay of the webcast will be available approximately tw

Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months. As part of its late-cycle review, the FDA has requested that the Company update its proposed Risk Evaluation Mitigation Strategy (REMS) to include liver monitorin

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application (NDA) for accelerated approval of sparsentan in IgA nephropathy (IgAN) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review; Prescription Drug User Fee Act (PDUFA) target action date set for November 17, 2022Total revenue for the second quarter 2022 was $54.2 million, consisting of $51.0 million in net product sales and $3.2 million in licensing and collaboration revenueCash, cash equivalents and marketable securities, as of June 30, 2022, totaled $553.2 million "

PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase 3 DUPLEX Study in 2023 Company and its partner Vifor Pharma applying for conditional marketing authorization of sparsentan for IgAN in Europe; review decision expected in second half of 2023 Pegtibatinase granted Breakthrough Therapy Designation by FDA Company to host conference call and webcast tomorrow at 8:00 a.m. ET SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today provided regulatory updates for its sparsentan programs in IgA nephropathy (IgA

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:00 a.m. ET. Conference Call Information                            Date: Thursday, August 4, 2022Time:      8:00 a.m. ETDial-in numbers: +1 (888) 220-8474 (U.S.) or +1 (313) 209-6544 (International)Confirmation code: 5371785Live webcast: Travere.com in the "Events & Presentations" section of the "Investors" page A replay of the call will

Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting Refinanced $207 million of 2025 convertible notes through offering of $316 million convertible senior notes due 2029 SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2022 financial results and provided a corporate update. New Drug Application (NDA) for accelerated approval of sparsentan in IgA nephropathy (IgAN) submitted to the U.S. Food and Drug Administration (

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date:Thursday, May 5, 2022Time:4:30 p.m. ETDial-in numbers:+1 (800) 289-0720 (U.S.) or +1 (313) 209-5140 (International)Confirmation code:7273768Live webcast:Travere.com in the "Events & Presentations" section of the "Investors" page A replay of the call will be available from 7:30 p.m. ET, May 5, 20

NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA nephropathy and FSGS MAA submission mid-year 2022 Recently reported positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria Net product sales increased six percent to $211 million for the full year 2021 SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2021 financial results and provided a corporate update. The Company is on-track to submit a New D

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date: Thursday, February 24, 2022Time: 4:30 p.m. ETDial-in numbers: +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)Confirmation code: 6217409Live webcast: Travere.com in the "Events & Presentations" section of the "Investors" page A replay of the call will be avai

Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results provide clinical proof of concept for first potential therapy targeting the underlying enzyme deficiency in classical homocystinuria Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria

Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of sparsentan in IgA nephropathy for accelerated approval under Subpart H expected in the first quarter of 2022 Based on FDA interactions, accelerated approval submission of sparsentan in FSGS planned for mid-2022, pending additional supportive eGFR data from the ongoing DUPLEX Study Joint collaboration with Vifor Pharma to commercialize sparsentan in Europe; combined IgA nephropathy and FSGS MAA submission for sparsentan in Europe expected mid-2022 Net product sales of $54.2 million for the third quarte

SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information  Date:Thursday, October 28, 2021Time:4:30 p.m. ETDial-in numbers:+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)Confirmation code:5068414Live webcast:Travere.com in the "Events & Presentations" section of the "Investors" page A replay of the call will be available from 7:30 p.m. ET, O

Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p<0.0001 To date in the study, sparsentan has been generally well-tolerated and consistent with the previously observed safety profile Submission of an NDA under Subpart H accelerated approval pathway in the U.S. expected in first half 2022 Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced positive topline interim results from the ongoing

Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track to report topline data from interim 36-week proteinuria endpoint in August 2021 Net product sales of $54.6 million for the second quarter of 2021 SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its second quarter 2021 financial results and provided a corporate update. Following interactions with the European Medicines Agency (EMA) during the second quarter of 2021, the Company expects to submit an application for conditional marketing aut

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date:Thursday, July 29, 2021Time:4:30 p.m. ETDial-in numbers:+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)Confirmation code:9790904Live webcast:Travere.com in the "Events & Presentations" section of the "Investors" page A replay of the call will be available from 7:30 p.m. ET, July 2